166 related articles for article (PubMed ID: 12072918)
1. Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators.
Büchner T; Fegeler W; Bernhardt H; Brockmeyer N; Duswald KH; Herrmann M; Heuser D; Jehn U; Just-Nübling G; Karthaus M; Maschmeyer G; Müller FM; Müller J; Ritter J; Roos N; Ruhnke M; Schmalreck A; Schwarze R; Schwesinger G; Silling G;
Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):337-52. PubMed ID: 12072918
[TBL] [Abstract][Full Text] [Related]
2. Management of mycoses in surgical patients -- review of the literature.
Holzheimer RG; Dralle H
Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912
[TBL] [Abstract][Full Text] [Related]
3. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
Rex JH; Walsh TJ; Sobel JD; Filler SG; Pappas PG; Dismukes WE; Edwards JE
Clin Infect Dis; 2000 Apr; 30(4):662-78. PubMed ID: 10770728
[TBL] [Abstract][Full Text] [Related]
4. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
5. Candida endophthalmitis: focus on current and future antifungal treatment options.
Khan FA; Slain D; Khakoo RA
Pharmacotherapy; 2007 Dec; 27(12):1711-21. PubMed ID: 18041891
[TBL] [Abstract][Full Text] [Related]
6. Deep Candida infections in the neutropenic and non-neutropenic host: an ISHAM symposium.
Tiraboschi IN; Bennett JE; Kauffman CA; Rex JH; Girmenia C; Sobel JD; Menichetti F
Med Mycol; 2000; 38 Suppl 1():199-204. PubMed ID: 11204146
[TBL] [Abstract][Full Text] [Related]
7. A case of Candida lambica fungemia misidentified as Candida krusei in an intravenous drug abuser.
Vervaeke S; Vandamme K; Boone E; De Laere E; Swinne D; Surmont I
Med Mycol; 2008 Dec; 46(8):853-6. PubMed ID: 18798049
[TBL] [Abstract][Full Text] [Related]
8. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005.
Borg-von Zepelin M; Kunz L; Rüchel R; Reichard U; Weig M; Gross U
J Antimicrob Chemother; 2007 Aug; 60(2):424-8. PubMed ID: 17562683
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies.
Myoken Y; Kyo T; Fujihara M; Sugata T; Mikami Y
Haematologica; 2004 Mar; 89(3):378-80. PubMed ID: 15020289
[TBL] [Abstract][Full Text] [Related]
12. Recent experience with fungaemia: change in species distribution and azole resistance.
Chakrabarti A; Chatterjee SS; Rao KL; Zameer MM; Shivaprakash MR; Singhi S; Singh R; Varma SC
Scand J Infect Dis; 2009; 41(4):275-84. PubMed ID: 19229762
[TBL] [Abstract][Full Text] [Related]
13. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Minari A; Hachem R; Raad I
Clin Infect Dis; 2001 Jan; 32(2):186-90. PubMed ID: 11170906
[TBL] [Abstract][Full Text] [Related]
14. [Candida albicans fungemia with pulmonary localization treated with fluconazole. A case report].
Thomas F; Mebtouche B; Clavier H; Kalfon P
Rev Pneumol Clin; 2000 Feb; 56(1):37-40. PubMed ID: 10740113
[TBL] [Abstract][Full Text] [Related]
15. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management.
Chen SC; Marriott D; Playford EG; Nguyen Q; Ellis D; Meyer W; Sorrell TC; Slavin M;
Clin Microbiol Infect; 2009 Jul; 15(7):662-9. PubMed ID: 19614718
[TBL] [Abstract][Full Text] [Related]
16. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
17. [Impact of antifungal prophylaxis on the gastrointestinal yeast colonisation in patients with haematological malignancies].
Rimek D; Redetzke K; Kappe R
Mycoses; 2006; 49 Suppl 2():18-23. PubMed ID: 17022757
[TBL] [Abstract][Full Text] [Related]
18. [Controversy concerning optimal prophylaxis and empirical antifungal therapy in immunocompromised patients].
Zielińska E
Przegl Epidemiol; 2003; 57(2):299-307. PubMed ID: 12910598
[TBL] [Abstract][Full Text] [Related]
19. Empirical antifungal therapy in treating febrile neutropenic patients.
Wingard JR
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S38-43. PubMed ID: 15250019
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological characteristics of fatal Candida krusei fungemia in immunocompromised febrile neutropenic children.
Agirbasli H; Otlu B; Bilgen H; Durmaz R; Gedikoglu G
Infection; 2008 Feb; 36(1):88-91. PubMed ID: 18084719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
